查看文章

Objective:

To investigate efficacy and safety of St. John's wort (SJW) LI 160 in somatoform disorders.

Methods:

In a prospective, randomized, placebo-controlled, and double-blind parallel group study, 184 outpatients with somatization disorder (ICD-10 F45. 0), undifferentiated somatoform disorder (F45. 1), and somatoform autonomic dysfunction (F45. 3), but not major depression, received either 300 mg of SJW extract LI 160 twice daily or matching placebo for 6 weeks. Six outcome measures were evaluated as a combined measure by means of the Wei Lachin test: Somatoform Disorders Screening Instrument–7 days (SOMS-7), somatic subscore of the HAMA, somatic subscore of the SCL-90-R, subscores “improvement” and “efficacy” of the CGI, and the global judgment of efficacy by the patient.

Results:

In the intention to treat population (N= 173), for each of the six primary efficacy measures as well as for the …